H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on PepGen (PEPG) to $14 from $16 and keeps a Buy rating on the shares after the company announced that the results from the PGN-EDO51 cohort from the CONNECT1 cohort are scheduled to readout in Q3.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG: